[Antifibrotic therapy and progressive lung fibrosis]

Area of Science:

• Pulmonology
• Fibrotic Interstitial Lung Diseases

Background:

• Fibrosing interstitial pneumonia (FIP) affects a significant patient proportion, with up to 40% developing a progressive phenotype.
• This progressive FIP shares genetic, pathogenic, and clinical similarities with idiopathic pulmonary fibrosis (IPF).

Purpose of the Study:

• To evaluate the efficacy of antifibrotic agents in patients with progressive fibrosing interstitial lung disease (PF-ILD).
• To explore the potential of pirfenidone and nintedanib in managing PF-ILD, drawing parallels with their established use in IPF.

Main Methods:

• Review of existing studies and clinical data on antifibrotic treatment in PF-ILD.
• Comparative analysis of treatment outcomes in PF-ILD patients receiving pirfenidone or nintedanib versus control groups.

Main Results:

• Preliminary studies indicate encouraging results for antifibrotic therapies in PF-ILD.
• Pirfenidone and nintedanib demonstrate potential efficacy, mirroring their effects in IPF patients.

Conclusions:

• Antifibrotic agents like pirfenidone and nintedanib are potential therapeutic options for progressive fibrosing interstitial lung disease.
• Larger-scale studies are required to confirm these initial encouraging findings and establish definitive treatment guidelines.